Your browser doesn't support javascript.
loading
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
Willis, M D; Harding, K E; Pickersgill, T P; Wardle, M; Pearson, O R; Scolding, N J; Smee, J; Robertson, N P.
Afiliação
  • Willis MD; Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, UK/Department of Neurology, University Hospital of Wales, UK.
  • Harding KE; Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, UK/Department of Neurology, University Hospital of Wales, UK.
  • Pickersgill TP; Department of Neurology, University Hospital of Wales, UK.
  • Wardle M; Department of Neurology, University Hospital of Wales, UK.
  • Pearson OR; Department of Neurology, Morriston Hospital, UK.
  • Scolding NJ; Department of Neurology, Southmead Hospital, UK.
  • Smee J; Department of Neurology, University Hospital of Wales, UK.
  • Robertson NP; Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, UK/Department of Neurology, University Hospital of Wales, UK RobertsonNP@cardiff.ac.uk.
Mult Scler ; 22(9): 1215-23, 2016 08.
Article em En | MEDLINE | ID: mdl-26514979
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Alemtuzumab / Imunossupressores Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Alemtuzumab / Imunossupressores Idioma: En Ano de publicação: 2016 Tipo de documento: Article